Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Flovent Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

NCT00280358
View directory record Official record
Conditions
Healthy
Interventions
Fluticasone Propionate, Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2008 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

NCT02577497
View directory record Official record
Conditions
Asthma
Interventions
beclomethasone, fluticasone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

NCT01725685
View directory record Official record
Conditions
Asthma
Interventions
FF 400 mcg, UMEC 500 mcg, FF/UMEC 400/500 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

NCT00633217
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 29, 2026, 6:41 PM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 29, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional

Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation

NCT07396987
View directory record Official record
Conditions
Asthma Attack, Asthma Control, Asthma Exacerbations, Asthma
Interventions
ER-Initiated Telehealth Referral
Behavioral
Lead sponsor
Juan Carlos Cardet
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 6:41 PM EDT
Not listed No phase listed Observational

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

NCT05246085
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cortisol level
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 29, 2026, 6:41 PM EDT
Terminated Phase 4 Interventional

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

NCT00071552
View directory record Official record
Conditions
Asthma
Interventions
Qvar, Flovent Diskus
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

NCT01156792
View directory record Official record
Conditions
Asthma
Interventions
FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01086410
View directory record Official record
Conditions
Asthma
Interventions
Placebo Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Placebo Oral Capsule, Prednisolone Oral Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Cypress, California • Huntington Beach, California • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety

NCT01622569
View directory record Official record
Conditions
Bilateral Nasal Polyposis
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

NCT00895817
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Swallowed fluticasone, Esomeprazole
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth

NCT01520688
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Fluticasone, Budesonide, Beclomethasone, Budesonide, Fluticasone
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 29, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children

NCT03040596
View directory record Official record
Conditions
Vocal Fold Nodules
Interventions
Fluticasone propionate, Standard voice therapy
Drug · Behavioral
Lead sponsor
Joseph Dohar, MD
Other
Eligibility
4 Years to 11 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease

NCT01124422
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone propionate/salmeterol inhalation powder DISKUS 250/50, tiotropium bromide inhalation powder HandiHaler
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

NCT00452699
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

NCT00655109
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Olopatadine, Fluticasone, Saline, Artificial tears
Drug
Lead sponsor
Greiner, Jack V., OD DO PhD
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 29, 2026, 6:41 PM EDT
Completed No phase listed Observational

Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps

NCT01777906
View directory record Official record
Conditions
Size of Nasal Polyps, Control of Symptoms
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
17 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Withdrawn Phase 2 Interventional

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

NCT01209715
View directory record Official record
Conditions
COPD
Interventions
Placebo, Fluticasone /salmeterol
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

NCT01117116
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate and salmeterol, budesonide and formoterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

NCT02593123
View directory record Official record
Conditions
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Interventions
mycophenolate mofetil, Sargramostim, Filgrastim
Drug · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 29, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00883168
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
45
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 29, 2026, 6:41 PM EDT